Brage Storstein Andresen, PhD, FRCPath (UK)

Brage S. Andresen, PhD, FRCPath, is professor of human molecular genetics and head of translational biology at SDU and CSO of Inverna Therapeutics. He holds a PhD in medicine from Aarhus University and is a fellow of the Royal Society of Pathology, UK (FRCPath).   

He has more than 30 years of experience in molecular genetics with a special emphasis on regulation of normal and aberrant pre-mRNA splicing in human disease. 

In recent years his lab has had a special focus on pseudo-exons and have developed software to identify them and methods to modulate the splicing of pseudo-exons as a new therapeutic approach. Prof. Andresen’s lab has developed splice switching oligonucleotides (SSOs) for general and allele-specific targeting of LRRK2 as a potential new therapy for Parkinson’s disease. Prof. Andresen has published more than 150 scientific papers and several patents.

In 2024 he co-founded Inverna Therapeutics, an RNA-medicine company, which develops RNA-precision medicines.